The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
 
Michael White
No Relationships to Disclose
 
Christopher P. Vellano
No Relationships to Disclose
 
Miles Cameron Andrews
Honoraria - MSD Australia; MSD Australia
Consulting or Advisory Role - BMS Australia (Inst)
Research Funding - MSD Australia (Inst)
 
Russell G. Witt
No Relationships to Disclose
 
Manoj Chelvanambi
No Relationships to Disclose
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb/Roche; Merck
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Elizabeth M. Burton
No Relationships to Disclose
 
Yanshuo Chu
Employment - MD Anderson Cancer Center
 
Matthew J Lastrapes
No Relationships to Disclose
 
Mike R. Lau
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis
 
Hiya Banerjee
Employment - Novartis Pharmaceuticals UK Ltd.
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; BMS; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; NanoString Technologies; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Scott Eric Woodman
Stock and Other Ownership Interests - WEAVR Health
 
Linghua Wang
No Relationships to Disclose
 
Amy E. Moran
Research Funding - AstraZeneca/MedImmune
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Timothy Heffernan
Stock and Other Ownership Interests - Cullgen; Silicon Therapeutics
Honoraria - Tango Therapeutics
Consulting or Advisory Role - Cullgen; Silicon Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - I am a con-inventor on material and method of use patents for therapeutics developed within MD Anderson. I may personnaly benefit from milestone and royalty agreements through MDA alliances and outlicense agreements.
Travel, Accommodations, Expenses - Cullgen; Tango Therapeutics
 
Joe R. Marszalek
Patents, Royalties, Other Intellectual Property - Milestones from Boehringer Ingelheim.; Patent on IACS-010759, and OXPHOS complex I inhibitor is held by UT MD Anderson Cancer Center. (Inst)
 
Jennifer Ann Wargo
Stock and Other Ownership Interests - Micronoma
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis